MLICM
HUMA icon

Metropolitan Life Insurance Company (MetLife)’s Humacyte HUMA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,483
Closed -$4.61K – 987
2024
Q1 		$4.61K Buy
1,483
+185
+14% +$622 ﹤0.01% 2251
2023
Q4 		$3.69K Sell
1,298
-2,274
-64% -$5.84K ﹤0.01% 2301
2023
Q3 		$10.5K Hold
3,572
– – ﹤0.01% 2184
2023
Q2 		$10.2K Hold
3,572
– – ﹤0.01% 2288
2023
Q1 		$11K Sell
3,572
-547
-13% -$1.55K ﹤0.01% 2123
2022
Q4 		$8.69K Buy
+4,119
New +$12.5K ﹤0.01% 2313

Other funds holding HUMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s HUMA Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Humacyte (HUMA) in Q2 2024, closing a stake of 1,483 shares — an estimated $4.61K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in HUMA in Q4 2022 and held it in 6 quarters. The position peaked at $11K in Q1 2023. 123 funds tracked by Wall St. Rank hold HUMA as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Humacyte position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,483 Humacyte shares in Q2 2024, an estimated $4.61K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Humacyte in Q4 2022 and held it in 6 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Humacyte position peaked at $11K in Q1 2023.
  • 123 funds tracked by Wall St. Rank held Humacyte as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.